|  |
| --- |
| **Supplementary Table 2.** PFS and OS in the subgroups identified by the combined assessment of *HER2* CNV and HER2 IHC or the combined assessment of *HER2* CNV and AMNESIA panel |
| **Subgroups** | ***N (%)*** | **mPFS** | **HR** | ***p*** | **mOS** | **HR** | ***p*** |
| *HER2* CNV-low/HER2 2+ | 103 (31.5%) | 6.3 | ref | ref | 13.0 | Ref | ref |
| *HER2* CNV-high/HER2 2+ | 12 (3.7%) | 5.7 | 0.99 (0.53-1.84) | 0.966 | 13.1 | 1.13 (0.58-2.18) | 0.724 |
| *HER2* CNV-low/HER2 3+ | 61 (18.7%) | 7.4 | 0.93 (0.67-1.29) | 0.671 | 12.7 | 1.07 (0.74-1.53) | 0.723 |
| *HER2* CNV-high/HER2 3+ | 151 (46.2%) | 10.7 | 0.44 (0.34-0.59) | <0.001 | 21.7 | 0.53 (0.38-0.72) | <0.001 |
| *HER2* CNV-low/AMNESIA - | 129 (39.4%) | 6.6 | ref | ref | 13.7 | ref | ref |
| *HER2* CNV-low/AMNESIA + | 35 (10.7%) | 6.2 | 1.34 (0.91-1.96) | 0.137 | 10.7 | 1.52 (1.01-2.3) | 0.046 |
| *HER2* CNV-high/AMNESIA - | 147 (45.0%) | 10.5 | 0.51 (0.39-0.67) | <0.001 | 20.3 | 0.6 (0.45-0.81) | <0.001 |
| *HER2*  CNV-high/AMNESIA + | 16 (4.9%) | 10.2 | 0.49 (0.26-0.91) | 0.025 | 21.8 | 0.53 (0.26-1.09) | 0.084 |
| CNV, copy number variation; IHC, immunohistochemistry; mPFS, median progression-free survival; mOS, median overall survival. |